mugiwara

TOP 100

mugiwara 17/01/20 12:44

Ha recomendado Re: Farmas USA de Triskis

mugiwara 16/01/20 16:23

Ha recomendado Re: Farmas USA de framus_morrigan

mugiwara 16/01/20 16:23

Ha recomendado Re: Farmas USA de anaramos

mugiwara 16/01/20 09:47

Ha recomendado Re: Farmas USA de Nachete96

mugiwara 15/01/20 19:21

Ha recomendado Re: Farmas USA de Chartis

mugiwara 15/01/20 17:57

Ha recomendado Re: Farmas USA de

lgonber

mugiwara 15/01/20 17:57

Ha recomendado Re: Farmas USA de

lgonber

mugiwara 15/01/20 17:57

Ha recomendado Re: Farmas USA de Chartis

mugiwara 15/01/20 17:56

Ha recomendado Re: Farmas USA de patoulax

mugiwara 15/01/20 17:56

Ha recomendado Re: Farmas USA de framus_morrigan

mugiwara 15/01/20 16:22

Ha recomendado Re: Farmas USA de framus_morrigan

mugiwara 15/01/20 16:22

Ha recomendado Re: Farmas USA de patoulax

mugiwara 15/01/20 16:20

Ha recomendado Re: Farmas USA de patoulax

mugiwara 15/01/20 16:20

Ha recomendado Re: Farmas USA de Triskis

mugiwara 15/01/20 16:20

Ha recomendado Re: Farmas USA de anaramos

mugiwara 15/01/20 16:19

Ha recomendado Re: Farmas USA de anaramos

mugiwara 15/01/20 16:19

Ha recomendado Re: Farmas USA de framus_morrigan

mugiwara 15/01/20 16:18

Ha recomendado Re: Farmas USA de patoulax

mugiwara 15/01/20 14:31

Ha recomendado Re: Farmas USA de framus_morrigan

mugiwara 15/01/20 14:31

Ha recomendado Re: Farmas USA de patoulax

mugiwara 15/01/20 14:30

Ha recomendado Re: Farmas USA de Investing_saints

mugiwara 15/01/20 14:30

Ha recomendado Re: Farmas USA de

lgonber

mugiwara 15/01/20 14:17

Ha recomendado Re: Farmas USA de framus_morrigan

mugiwara 15/01/20 14:17

Ha recomendado Re: Farmas USA de anaramos

mugiwara 15/01/20 14:17

Ha respondido al tema Farmas USA

CLVSPDUFA 15 de mayo.  Clovis Oncology’s Rubraca® (Rucaparib) Granted FDA Priority Review For Advanced Prostate Cancer Clovis seeks U.S. approval for rucaparib as monotherapy treatment for patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer- FDA submission based on data from TRITON clinical program in advanced prostate cancer- FDA has assigned PDUFA date of May 15, 2020 https://ir.clovisoncology.com/investors-and-news/news-releases/press-release-details/2020/Clovis-Oncologys-Rubraca-rucaparib-Granted-FDA-Priority-Review-for-Advanced-Prostate-Cancer/default.aspx 

Ir a respuesta